| Drug Name | ***0111 |
| Description |
A bispecific antibody targeting CD3 and CD19 is in preclinical studies for the treatment of acute lymphocytic leukemia and lymphoma. |
| Target | CD3; CD19 |
| Drug Modality | Antibody |
| Indication | Acute Lymphocytic Leukemia; Lymphoma |
| Product Category | Cancer Immunotherapy |
| Mechanism of Action | Anti-CD19; Anti-CD3 |
| Status | Preclinical |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |